EGFR and non-small cell lung carcinoma: Previous studies have reported that NSCLC harboring EGFR mutations, particularly those with acquired resistance mediated by a T790M and trans-C797S configurations, are sensitive to a combination therapy of a first-generation EGFR-TKI plus osimertinib (17–20).